alendronate has been researched along with Peritoneal Carcinomatosis in 2 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We established an in vivo ovarian cancer model with i." | 1.33 | Alendronate inhibits intraperitoneal dissemination in in vivo ovarian cancer model. ( Hashimoto, K; Ikebuchi, Y; Kawagishi, R; Morishige, K; Murata, Y; Sakata, M; Sawada, K; Tahara, M; Tasaka, K, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, J | 1 |
| Huang, X | 1 |
| Liu, P | 1 |
| Qiu, M | 1 |
| Li, B | 1 |
| Wen, Y | 1 |
| Li, Y | 1 |
| Wang, Q | 1 |
| Wu, M | 1 |
| Chen, Y | 1 |
| Pan, Y | 1 |
| Hashimoto, K | 1 |
| Morishige, K | 1 |
| Sawada, K | 1 |
| Tahara, M | 1 |
| Kawagishi, R | 1 |
| Ikebuchi, Y | 1 |
| Sakata, M | 1 |
| Tasaka, K | 1 |
| Murata, Y | 1 |
2 other studies available for alendronate and Peritoneal Carcinomatosis
| Article | Year |
|---|---|
Engineering Alendronate-Composed Iron Nanochelator for Efficient Peritoneal Carcinomatosis Treatment.
Topics: Alendronate; Animals; Cell Line, Tumor; Humans; Iron; Iron Chelating Agents; Mice; Peritoneal Neopla | 2022 |
Alendronate inhibits intraperitoneal dissemination in in vivo ovarian cancer model.
Topics: Alendronate; Animals; CA-125 Antigen; Cell Line, Tumor; Disease Progression; Female; Mice; Mice, Inb | 2005 |